According to the agreement, the aim is to sell Novo Nordisk's diet products Ozempic and Wegovy on the Hims & Hers platform.
Novo Nordisk also states that it will withdraw a lawsuit against Hims & Hers if the platform stops marketing low-priced copies of its products.
Hims & Hers shares are surging 50 percent in futures trading. Novo Nordisk shares - which have lost more than half their value in a year due to research setbacks and advances by competitors - are also up about 2 percent on the Copenhagen Stock Exchange.
